wellrank.ai

Which telehealth services still offer compounded GLP-1s after the FDA crackdown?

ClaudequalifiedCollected Jun 30, 2026, 13:27 UTC

Verbatim response from Claude

This is a fast-moving situation, so I want to be straightforward with you:

What Happened

The FDA declared the semaglutide shortage over (early 2025), which banned most compounding pharmacies from making compounded semaglutide. Tirzepatide compounding is also under pressure.

Services That Were Still Navigating This Space (verify current status):

  • Hims & Hers - fought back legally and continued briefly, but faced significant restrictions
  • Ro - largely shifted to brand-name medications
  • Henry - moved toward branded options
  • LifeMD - similar transition

Honest Reality Check:

  • Most major telehealth platforms have stopped or significantly reduced compounded GLP-1 offerings as of mid-2025
  • Some smaller compounding pharmacies may still operate in a gray area
  • The legal landscape is actively changing - what's available today may differ next week

What I'd Recommend:

  1. Check each service's current website directly - policies change weekly
  2. Ask specifically whether they're offering branded Ozempic/Wegovy/Zepbound instead
  3. Be cautious of services claiming to still offer compounded versions without clear FDA compliance explanations

Would you like help thinking through the branded medication access options instead, which may be more stable?

Brands mentioned in this answer

Is this answer wrong about your brand?

AI engines repeat outdated pricing, wrong ingredients, and misread positioning every day. Tell us what this answer gets wrong and we will include a correction review in your free AI Visibility Audit.

This answer is reproduced verbatim from the engine's API at collection time and may contain errors or outdated claims. It is presented as evidence of what AI engines tell buyers, not as medical or purchasing advice.

Is your brand missing from this answer?

Get your AI Visibility Audit: every buyer intent question you are losing, who wins them, and the sources that decide the answer.